Ironwood Pharmaceuticals ($NASDAQ:IRWD), Inc. is a biopharmaceutical company that focuses on the development and commercialization of innovative medicines that address unmet needs in gastrointestinal (GI) diseases. The company has developed several products that are used to treat GI conditions such as irritable bowel syndrome, reflux and constipation. Ironwood’s pipeline also includes potential treatments for a variety of additional GI conditions. The new funds will be used to further research and development efforts and to fund market launches of its products. Ironwood is dedicated to developing drugs that improve the lives of patients suffering from GI diseases, and the new funding will help them continue this mission.
This new investment is a major milestone for Ironwood Pharmaceuticals, which is working to become a leading player in the GI pharmaceuticals market. The firm is committed to developing life-changing treatments that will improve the quality of life for GI patients around the world. With the recent investment from Robeco Institutional Asset Management B.V., Ironwood is well-positioned to make a significant impact in the industry.
This investment should be seen as a vote of confidence in Ironwood’s potential as the company continues to develop innovative treatments for various gastrointestinal conditions. With the support of Robeco, Ironwood is poised to reach new heights in the coming years. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Ironwood Pharmaceuticals. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Ironwood Pharmaceuticals. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Ironwood Pharmaceuticals. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Ironwood Pharmaceuticals are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
GoodWhale has analyzed the financials of IRONWOOD PHARMACEUTICALS and based on our Star Chart, we have determined that the company has an intermediate health score of 6/10. This is due to its cashflows and debt, which suggest it is likely to pay off debt and fund future operations. In terms of its other financials, IRONWOOD PHARMACEUTICALS is strong in asset and profitability, medium in growth and weak in dividend. Based on this, we have classified IRONWOOD PHARMACEUTICALS as an ‘elephant’, which is a type of company that is rich in assets after deducting off liabilities. Given IRONWOOD PHARMACEUTICALS’s financials, it is likely to be attractive to value investors who are looking for stable companies with strong asset bases. It may also be attractive to investors seeking steady dividend returns. More…
Risk Rating Analysis
Star Chart Analysis
Its competitors are Sun Pharma Advanced Research Co Ltd, Strides Pharma Science Ltd, Glenmark Pharmaceuticals Ltd.
– Sun Pharma Advanced Research Co Ltd ($BSE:532872)
Sun Pharma Advanced Research Co Ltd has a market cap of 70.81B as of 2022. The company’s Return on Equity is -429.91%. Sun Pharma Advanced Research Co Ltd is a pharmaceutical company that specializes in the research and development of new drugs and therapies. The company’s products are sold in over 100 countries worldwide.
– Strides Pharma Science Ltd ($BSE:532531)
Strides Pharma Science Ltd is a pharmaceutical company with a market cap of 29.66B as of 2022. The company has a Return on Equity of -10.94%. The company’s main products are generic drugs and active pharmaceutical ingredients. The company operates in over 50 countries and has over 10,000 employees.
– Glenmark Pharmaceuticals Ltd ($BSE:532296)
Glenmark Pharmaceuticals is a pharmaceutical company headquartered in Mumbai, India. The company was founded in 1977 by Gracias Saldanha as a generic drug manufacturer. The company has over 8,000 employees and operates in over 40 countries. The company’s product portfolio includes drugs in the areas of cardiology, dermatology, diabetes, oncology, respiratory, and urology.
Ironwood Pharmaceuticals, Inc. is a pharmaceutical company based in Cambridge, Massachusetts. While the stock price dropped on the same day, analysis of Ironwood’s financials suggest that the long-term outlook is still positive. With a healthy balance sheet and strong cash flow generation, Ironwood has the potential to provide investors with attractive returns. The company is focused on developing innovative treatments for gastrointestinal and cardiovascular diseases, as well as cancer and diabetes.
Additionally, its research and development initiatives have yielded promising results. With a robust pipeline and a broad portfolio of approved medications, Ironwood looks to be in a good position moving forward. Investors should be mindful of the market risks associated with pharmaceutical stocks, but Ironwood appears to offer a solid long-term opportunity.